• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

锕和铋靶向α治疗概述

An Overview of Targeted Alpha Therapy with Actinium and Bismuth.

作者信息

Morgenstern Alfred, Apostolidis Christos, Kratochwil Clemens, Sathekge Mike, Krolicki Leszek, Bruchertseifer Frank

机构信息

European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.

出版信息

Curr Radiopharm. 2018;11(3):200-208. doi: 10.2174/1874471011666180502104524.

DOI:10.2174/1874471011666180502104524
PMID:29732998
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6237921/
Abstract

BACKGROUND

Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy.

OBJECTIVE AND CONCLUSION

This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.

摘要

背景

近期关于225Ac标记的PSMA-617治疗转移性去势抵抗性前列腺癌具有显著疗效的报道突显了靶向α治疗的临床潜力。

目的与结论

本综述描述了225Ac及其子核素213Bi的生产方法，并总结了这两种α发射体目前的临床经验，特别关注膀胱癌、脑肿瘤、神经内分泌肿瘤和前列腺癌靶向α治疗的近期研究。

相似文献

1
An Overview of Targeted Alpha Therapy with Actinium and Bismuth.锕和铋靶向α治疗概述
Curr Radiopharm. 2018;11(3):200-208. doi: 10.2174/1874471011666180502104524.
2
The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications.锕-225和铋-213在靶向α治疗（TAT）中的临床作用演变——生产、放射性药物研发及临床应用
Curr Radiopharm. 2018;11(3):154-155. doi: 10.2174/187447101103180911115600.
3
Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.铋 - 213和锕 - 225用于血液系统恶性肿瘤的临床研究
Curr Radiopharm. 2018;11(3):192-199. doi: 10.2174/1874471011666180525102814.
4
Development of Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences.锕系放射性药物的发展：加拿大 TRIUMF 实验室的观点与经验
Curr Radiopharm. 2018;11(3):156-172. doi: 10.2174/1874471011666180416161908.
5
NorthStar Perspectives for Actinium-225 Production at Commercial Scale.商业规模生产锕-225的北极星视角
Curr Radiopharm. 2018;11(3):180-191. doi: 10.2174/1874471011666180515123848.
6
Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.使用铋-213和锕-225的靶向α疗法：满足未来需求。
J Labelled Comp Radiopharm. 2019 Sep;62(11):794-802. doi: 10.1002/jlcr.3792. Epub 2019 Aug 1.
7
Targeted alpha therapy with 213Bi.使用213Bi的靶向α治疗。
Curr Radiopharm. 2011 Oct;4(4):295-305. doi: 10.2174/1874471011104040295.
8
The Production of Ac-225.锕-225的产生
Curr Radiopharm. 2018;11(3):173-179. doi: 10.2174/1874471011666180418141357.
9
Evaluation of [Ac]Ac-DOTA for α-Therapy of Bone Metastases.用于骨转移α治疗的[Ac]Ac-DOTA评估。
Curr Radiopharm. 2018;11(3):223-230. doi: 10.2174/1874471011666180604083911.
10
Efforts to control the errant products of a targeted in vivo generator.控制靶向体内发生器的错误产物的努力。
Cancer Res. 2005 Jun 1;65(11):4888-95. doi: 10.1158/0008-5472.CAN-04-3096.

引用本文的文献

1
It's a match: use of the radionuclide theranostic pair La/Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies.成功匹配：放射性核素诊疗对La/Ac用于表皮生长因子受体靶向单域抗体的放射药理学特性研究
EJNMMI Radiopharm Chem. 2025 Jun 19;10(1):31. doi: 10.1186/s41181-025-00354-7.
2
In situ radiochemical doping of functionalized inorganic nanoplatforms for theranostic applications: a paradigm shift in nanooncology.用于诊疗应用的功能化无机纳米平台的原位放射化学掺杂：纳米肿瘤学的范式转变
J Nanobiotechnology. 2025 Jun 2;23(1):407. doi: 10.1186/s12951-025-03472-1.
3
Gamma camera imaging characteristics of Pb as a theragnostic pair for targeted alpha therapy: a feasibility study.

本文引用的文献

1
Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with Bi-substance P analogue.局部注射靶向 α 治疗与双 P 物质类似物后，继发性神经胶质瘤的存活时间延长。
Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1636-1644. doi: 10.1007/s00259-018-4015-2. Epub 2018 Apr 30.
2
Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study.用针对表皮生长因子受体的 α 发射器免疫缀合物治疗膀胱原位癌：一项初步研究。
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1364-1371. doi: 10.1007/s00259-018-4003-6. Epub 2018 Apr 11.
3
用于靶向α治疗的铅作为诊疗一体化对的γ相机成像特性：一项可行性研究。
EJNMMI Phys. 2025 May 27;12(1):50. doi: 10.1186/s40658-025-00763-2.
4
Emerging innovations in theranostics for pancreatic neuroendocrine tumors.胰腺神经内分泌肿瘤诊疗一体化的新兴创新技术。
NPJ Precis Oncol. 2025 May 19;9(1):146. doi: 10.1038/s41698-025-00938-1.
5
SLAMF receptors: key regulators of tumor progression and emerging targets for cancer immunotherapy.信号淋巴细胞激活分子家族受体：肿瘤进展的关键调节因子及癌症免疫治疗的新兴靶点
Mol Cancer. 2025 May 17;24(1):145. doi: 10.1186/s12943-025-02308-8.
6
[Ac]Ac-PSMA-617 production method: development of an efficient and reproducible radiolabelling process for establish a clinical routine production.[锕]锕-PSMA-617生产方法：开发一种高效且可重复的放射性标记工艺以建立临床常规生产。
EJNMMI Radiopharm Chem. 2025 May 4;10(1):20. doi: 10.1186/s41181-025-00344-9.
7
In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with Ac.用锕标记的抗HER2抗体偶联物的体外和体内评估
EJNMMI Radiopharm Chem. 2025 Apr 4;10(1):16. doi: 10.1186/s41181-025-00337-8.
8
[Radionuclide therapy in 2025: nuclear medicine options in the treatment of metastatic castration-resistant prostate cancer].《2025年放射性核素治疗：转移性去势抵抗性前列腺癌治疗中的核医学选择》
Urologie. 2025 Mar;64(3):237-245. doi: 10.1007/s00120-025-02526-4. Epub 2025 Feb 21.
9
Review of the anatomical basis for predicting plutonium alpha particle radiation induced osteogenic cancers.预测钚α粒子辐射诱发成骨肉瘤的解剖学基础综述。
Anat Rec (Hoboken). 2025 Feb 18. doi: 10.1002/ar.25641.
10
Experimental study of iodine-131 labeling of a novel tumor-targeting peptide, TFMP-Y4, in the treatment of hepatocellular carcinoma with internal irradiation.新型肿瘤靶向肽TFMP-Y4的碘-131标记用于内照射治疗肝细胞癌的实验研究
BMC Cancer. 2025 Feb 12;25(1):245. doi: 10.1186/s12885-025-13666-3.
In vitro evaluation of Ac-DOTA-substance P for targeted alpha therapy of glioblastoma multiforme.
体外评价 Ac-DOTA-神经激肽 SP 用于多形性胶质母细胞瘤的靶向 α 治疗。
Chem Biol Drug Des. 2018 Jul;92(1):1344-1356. doi: 10.1111/cbdd.13199. Epub 2018 Apr 23.
4
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control.针对转移性去势抵抗性前列腺癌的靶向 α 治疗：Ac-PSMA-617 的游泳者图分析提示了肿瘤控制持续时间的疗效。
J Nucl Med. 2018 May;59(5):795-802. doi: 10.2967/jnumed.117.203539. Epub 2018 Jan 11.
5
An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy.一种用于锕-225 靶向 α 治疗的十八元大环配体。
Angew Chem Int Ed Engl. 2017 Nov 13;56(46):14712-14717. doi: 10.1002/anie.201709532. Epub 2017 Oct 16.
6
More α Than β for Prostate Cancer?前列腺癌中α比β更多？
J Nucl Med. 2017 Nov;58(11):1709-1710. doi: 10.2967/jnumed.117.198333. Epub 2017 Sep 21.
7
Targeted alpha therapy of mCRPC: Dosimetry estimate of Bismuth-PSMA-617.mCRPC 的靶向 alpha 治疗：铋-PSMA-617 的剂量学估计。
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):31-37. doi: 10.1007/s00259-017-3817-y. Epub 2017 Sep 11.
8
Simultaneous Separation of Actinium and Radium Isotopes from a Proton Irradiated Thorium Matrix.从质子辐照钍基体中同时分离锕和镭同位素
Sci Rep. 2017 Aug 15;7(1):8216. doi: 10.1038/s41598-017-08506-9.
9
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.转移性去势抵抗性前列腺癌的靶向 α 治疗：Ac-PSMA-617 的剂量估算和经验剂量探索。
J Nucl Med. 2017 Oct;58(10):1624-1631. doi: 10.2967/jnumed.117.191395. Epub 2017 Apr 13.
10
Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.Bi-PSMA-617靶向α放射性核素疗法治疗转移性去势抵抗性前列腺癌
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1099-1100. doi: 10.1007/s00259-017-3657-9. Epub 2017 Mar 2.